Skip to main content
. 2017 Jan 5;7:39899. doi: 10.1038/srep39899

Figure 2. Hepatic inhibition miR-291b-3p expression ameliorates hyperglycemia and insulin resistance in HFD-fed mice.

Figure 2

(A) Glucose tolerance test (GTT) in HFD-fed mice on 7 days after injection of adenovirus-miR-291b-3p-inbibitor (Ad-miR-291i) or adenovirus-GFP (Ad-NC). (B) Insulin tolerance test (ITT) in HFD-fed mice on 7 days after injection of Ad-miR-291i or Ad-NC. (C) Pyruvate tolerance test (PTT) in HFD-fed mice on 7 days after injection of Ad-miR-291i or Ad-NC. (D) Euglycemic-hyperinsulinemic clamp assay in HFD-fed mice on 7 days after injection of Ad-miR-291i or Ad-NC. (E) The glycogen content in the liver of HFD-fed mice on 7 days after injection of Ad-miR-291i or Ad-NC. (F) The glucose production in the liver of HFD-fed mice on 7 days after injection of Ad-miR-291i or Ad-NC. (G) The glycogen content in the NCTC1469 cells transfected with miR-291b-3p inhibitor (291i). (H) The glucose level in the medium of NCTC1469 cells transfected with 291i. Data are expressed as mean ± SEM (n = 5). *P < 0.05; **P < 0.01 vs. control group.